Abstract
People with Alzheimer’ s disease (AD) commonly complain of sleep disturbances, which are seen in a wide variety of conditions that become more common in late life. It is not known whether sleep-related symptoms are associated with AD independently of their association with other illnesses. Secondary analyses of sleep-related measures collected through the Survey of Health, Ageing and Retirement in Europe (SHARE; i.e., sleeping problems, fatigue, taking sleeping medication, and trouble sleeping or a change in pattern) were conducted on those who reported the absence of AD or dementia at baseline. A ‘sleep disturbance index’ (SDI) using sleep-related measures was created and compared to a frailty index reflecting overall health status. Each sleep measure independently predicted self-reported AD or dementia and mortality within ~4 years. Combined, the SDI was associated with an increased risk of developing AD or dementia (OR= 1.23, 95%CI = 1.11-1.36) and mortality (OR = 1.18, 95% CI = 1.12-1.24), and remained a strong factor for dementia when overall health status was added to the risk model (p = 0.054). These findings indicate that sleep disturbance may exist prior to the manifestation of other typical symptoms observed in AD (e.g., memory loss). Sleep-related questions may be useful for screening individuals at risk for dementia and may allow for the earlier detection of AD at the preclinical stage.
Keywords: Alzheimer’s disease, dementia, mortality, sleep, circadian rhythms, frailty.
Current Alzheimer Research
Title:Sleep Disturbance is Associated with Incident Dementia and Mortality
Volume: 10 Issue: 7
Author(s): Roxanne Sterniczuk, Olga Theou, Benjamin Rusak and Kenneth Rockwood
Affiliation:
Keywords: Alzheimer’s disease, dementia, mortality, sleep, circadian rhythms, frailty.
Abstract: People with Alzheimer’ s disease (AD) commonly complain of sleep disturbances, which are seen in a wide variety of conditions that become more common in late life. It is not known whether sleep-related symptoms are associated with AD independently of their association with other illnesses. Secondary analyses of sleep-related measures collected through the Survey of Health, Ageing and Retirement in Europe (SHARE; i.e., sleeping problems, fatigue, taking sleeping medication, and trouble sleeping or a change in pattern) were conducted on those who reported the absence of AD or dementia at baseline. A ‘sleep disturbance index’ (SDI) using sleep-related measures was created and compared to a frailty index reflecting overall health status. Each sleep measure independently predicted self-reported AD or dementia and mortality within ~4 years. Combined, the SDI was associated with an increased risk of developing AD or dementia (OR= 1.23, 95%CI = 1.11-1.36) and mortality (OR = 1.18, 95% CI = 1.12-1.24), and remained a strong factor for dementia when overall health status was added to the risk model (p = 0.054). These findings indicate that sleep disturbance may exist prior to the manifestation of other typical symptoms observed in AD (e.g., memory loss). Sleep-related questions may be useful for screening individuals at risk for dementia and may allow for the earlier detection of AD at the preclinical stage.
Export Options
About this article
Cite this article as:
Sterniczuk Roxanne, Theou Olga, Rusak Benjamin and Rockwood Kenneth, Sleep Disturbance is Associated with Incident Dementia and Mortality, Current Alzheimer Research 2013; 10 (7) . https://dx.doi.org/10.2174/15672050113109990134
DOI https://dx.doi.org/10.2174/15672050113109990134 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Dampening the Progression of Dementia
Current Neurovascular Research Exploring Structural Requirements of Imaging Agents Against Aβ Plaques in Alzheimer’s Disease: A QSAR Approach
Combinatorial Chemistry & High Throughput Screening Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Traumatic Brain Injury: A Forensic Approach: A Literature Review
Current Neuropharmacology Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Sirtuins: Common Targets in Aging and in Neurodegeneration
Current Drug Targets Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Caspase-1-independent Maturation of IL-1β in Ischemic Brain Injury: is there a Role for Gelatinases?
Mini-Reviews in Medicinal Chemistry Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry